AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Ruifeng Xu

Ruifeng Xu

Central US Merck & Co., Inc. - / United States
Others
AD Scientific Index ID: 4381452
person_outline Ruifeng Xu's MOST POPULAR ARTICLES
1-) Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States Pharmacoeconomics 35 (8), 831-844, 2017
2-) Cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumab-naive patients with advanced melanoma in the United States Journal of managed care & specialty pharmacy 23 (2), 184-194, 2017
3-) EuroQol (EQ-5D) health utility scores for patients with migraine Quality of life research 20 (4), 601-608, 2011
4-) Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States Journal of medical economics 20 (2), 140-150, 2017
5-) EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs Health and Quality of Life Outcomes 10 (1), 65, 2012